<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03350386</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-017</org_study_id>
    <nct_id>NCT03350386</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of FYU-981 and Oxaprozin</brief_title>
  <official_title>Drug-drug Interaction Study to Evaluate the Pharmacokinetics and Safety of FYU-981 and Oxaprozin in Healthy Male Adults Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, 2-period add-on study to assess the drug-drug interaction between
      FYU-981 and oxaprozin. The purpose of this study is to investigate the pharmacokinetics of
      each period in a single administration of FYU-981 and concomitant administration of FYU-981
      with oxaprozin at steady -state in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2, 2017</start_date>
  <completion_date type="Actual">December 5, 2017</completion_date>
  <primary_completion_date type="Actual">December 5, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax: Maximum plasma concentration)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
    <description>T1/2: Elimination half-life of plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC: Area under the plasma concentration-time curve)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (kel: Elimination rate constant)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (MRT: Mean residence time)</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety (Incidence of treatment-emergent adverse event)</measure>
    <time_frame>20 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of FYU-981</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant administration of FYU-981 with oxaprozin at steady state</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FYU-981</intervention_name>
    <description>Single administration</description>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_label>Concomitant administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaprozin</intervention_name>
    <description>Repeated administration</description>
    <arm_group_label>Concomitant administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult healthy subjects

          -  Body mass index: &gt;=18.5 and &lt;25.0

        Exclusion Criteria:

          -  Subject with any disease or any history of disease that might be unsuitable for
             participation in the clinical study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagasawa Katsuaki</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P-One Clinic</name>
      <address>
        <city>Hachi≈çji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2017</study_first_submitted>
  <study_first_submitted_qc>November 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaprozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

